Antimicrobial Peptides: Do They Have a Future as Therapeutics?

Birkhauser Advances in Infectious Diseases

Volumn , Issue 9783319241975, 2016, Pages 147-154

  Zasloff, Michael ^a  

^a GEORGETOWN UNIVERSITY HOSPITAL   (United States)

Author keywords

Antimicrobial Peptide; Clinical Success Rate; Conventional Antibiotic; Skin Structure Infection; Topical Agent

Indexed keywords

EID: 85045453697     PISSN: 25043811     EISSN: 25043838     Source Type: Book Series    
DOI: 10.1007/978-3-319-24199-9_10     Document Type: Chapter

References (15)

1. Andes D, Craig W, Nielsen LA, Kristensen HH (2009) In vivo pharmacodynamic characterization of a novel plectasin antibiotic, NZ2114, in a murine infection model. Antimicrob Agents Chemother 53(7):3003–3009
2. Choi S, Isaacs A, Clements D, Liu D, Kim H, Scott RW, Winkler JD, DeGrado WF (2009) De novo design and in vivo activity of conformationally restrained antimicrobial arylamide foldamers. Proc Natl Acad Sci U S A 106(17):6968–6973
3. Ge Y, MacDonald D, Henry MM, Hait HI, Nelson KA, Lipsky BA, Zasloff MA, Holroyd KJ (1999a) In vitro susceptibility to pexiganan of bacteria isolated from infected diabetic foot ulcers. Diagn Microbiol Infect Dis 35(1):45–53
4. Ge Y, MacDonald DL, Holroyd KJ, Thornsberry C, Wexler H, Zasloff M (1999b) In vitro antibacterial properties of pexiganan, an analog of magainin. Antimicrob Agents Chemother 43(4): 782–788
5. Ge Y, MacDonald D, Hait H, Lipsky B, Zasloff M, Holroyd K (2002) Microbiological profile of infected diabetic foot ulcers. Diabet Med 19(12):1032–1034
6. Lipsky BA, Holroyd KJ, Zasloff M (2008) Topical versus systemic antimicrobial therapy for treating mildly infected diabetic foot ulcers: a randomized, controlled, double-blinded, multicenter trial of pexiganan cream. Clin Infect Dis 47(12):1537–1545
7. Mensa B, Howell GL, Scott R, DeGrado WF (2014) Comparative mechanistic studies of brilaci-din, daptomycin, and the antimicrobial peptide LL16. Antimicrob Agents Chemother 58(9): 5136–5145
8. Mygind PH, Fischer RL, Schnorr KM, Hansen MT, Sonksen CP, Ludvigsen S, Raventos D, Buskov S, Christensen B, De Maria L, Taboureau O, Yaver D, Elvig-Jorgensen SG, Sorensen MV, Christensen BE, Kjaerulff S, Frimodt-Moller N, Lehrer RI, Zasloff M, Kristensen HH (2005) Plectasin is a peptide antibiotic with therapeutic potential from a saprophytic fungus. Nature 437(7061):975–980
9. Schneider T, Kruse T, Wimmer R, Wiedemann I, Sass V, Pag U, Jansen A, Nielsen AK, Mygind PH, Raventos DS, Neve S, Ravn B, Bonvin AM, De Maria L, Andersen AS, Gammelgaard LK, Sahl HG, Kristensen HH (2010) Plectasin, a fungal defensin, targets the bacterial cell wall precursor Lipid II. Science 328(5982):1168–1172
10. Tew GN, Liu D, Chen B, Doerksen RJ, Kaplan J, Carroll PJ, Klein ML, DeGrado WF (2002) De novo design of biomimetic antimicrobial polymers. Proc Natl Acad Sci U S A 99(8): 5110–5114
11. Xiong YQ, Hady WA, Deslandes A, Rey A, Fraisse L, Kristensen HH, Yeaman MR, Bayer AS (2011) Efficacy of NZ2114, a novel plectasin-derived cationic antimicrobial peptide antibiotic, in experimental endocarditis due to methicillin-resistant Staphylococcus aureus. Antimicrob Agents Chemother 55(11):5325–5330
12. Zasloff M (1987) Magainins, a class of antimicrobial peptides from Xenopus skin: isolation, characterization of two active forms, and partial cDNA sequence of a precursor. Proc Natl Acad Sci U S A 84(15):5449–5453
13. Zasloff M (2002) Antimicrobial peptides of multicellular organisms. Nature 415(6870):389–395
14. Zhang Y, Teng D, Mao R, Wang X, Xi D, Hu X, Wang J (2014) High expression of a plectasin-derived peptide NZ2114 in Pichia pastoris and its pharmacodynamics, postantibiotic and synergy against Staphylococcus aureus. Appl Microbiol Biotechnol 98(2):681–694
15. Zhu S (2008) Discovery of six families of fungal defensin-like peptides provides insights into origin and evolution of the CSalphabeta defensins. Mol Immunol 45(3):828–838